Tsutomu Shimada

Alfred I. duPont Hospital for Children

Papers

2

Total Citations

60

H-Index

2

About

Dr. Tsutomu Shimada is a leading figure in the development of diagnostic tools for mucopolysaccharidoses (MPS), a group of devastating lysosomal storage disorders. His research centers on the application of high-throughput mass spectrometry for newborn screening and disease monitoring. Dr. Shimada’s major contribution is the creation of a novel, automated heparan sulfate assay, detailed in his most-cited 2014 paper (36 citations). This work, alongside his seminal study on newborn screening using tandem mass spectrometry (24 citations), has revolutionized the early detection of MPS. By enabling precise quantification of glycosaminoglycans (GAGs)—the key biomarkers for these disorders—his methods allow for timely intervention and improved patient outcomes. Dr. Shimada’s impact is profound, as his assays are now integral to clinical screening programs worldwide, offering hope for families affected by these rare, progressive conditions. His dedication to bridging analytical chemistry and clinical genetics has established him as a pivotal innovator in the fight against lysosomal diseases.

Research Focus

Key Achievements

2
H-Index
2
Papers
60
Total Citations
30
Avg Citations/Paper
🏆 Most Cited Paper
Novel heparan sulfate assay by using automated high-throughput mass spectrometry: Application to monitoring and screening for mucopolysaccharidoses
36 citations · 2014
📈 Most Prolific Year: 2014 (2 Papers)
🤝 Key Collaborators: 17
🏛 Institutions: Alfred I. duPont Hospital for Children

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago